Abstract: The present invention relates to an in-vivo bulking agent which can be used as a medicinal agent for prevention or treatment of at least one disease selected from the group consisting of urinary incontinence, fecal incontinence, and gastroesophageal reflux or as a filler for use in a plastic surgery procedure, and to a preparation method therefor. The in-vivo bulking agent can exhibit a bulking effect when injected into the body and particularly, is highly biocompatible because a first composition in which silicone particles are coated with a zwitterionic polymer having a surfactant property is introduced into a second composition, whereby the bulking agent can inhibit inflammatory reactions in vivo.
Type:
Grant
Filed:
June 11, 2020
Date of Patent:
February 13, 2024
Assignee:
KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
Inventors:
Kwang Dae Hong, Jihun Seo, Joon Bum Lee
Abstract: Disclosed herein is a drug delivery vehicle. The drug delivery vehicle includes a lipid nanoparticle core for enclosing a primary drug and a protective shell surrounding the lipid nanoparticle. Also disclosed herein is a drug delivery system including the drug delivery vehicle carrying the primary drug, a method of preparing the drug delivery system and a method of using the drug delivery system.
Abstract: The present invention relates generally to methods of use and compositions useful to reduce dark spots, age spots, and/or unwanted pigmentation of skin. The composition includes a combination of niacinamide, phytic acid, Rosmarinus officinalis leaf extract, Chondrus crispus extract, and a combination of Saxifraga sarmentosa extract, Carica papaya (papaya) fruit extract, and Psidium guajava (guava) fruit extract. The composition is effective to reduce dark spots, age spots, and/or unwanted pigmentation of skin. The composition is effective to inhibit tyrosinase and/or Peroxisome Proliferator-Activated Receptor Gamma (PPAR-?) activity. The composition is further effective to reduce melanin content in skin, particularly dark skin, in some instances by at least 30%.